Document is current
Any future updates will be listed below
-
Authors
Morin, Gabriel https://orcid.org/0000-0002-8423-6701
Galasso, Ilaria
Canaud, Guillaume https://orcid.org/0000-0002-9901-8635
-
Funding
Funding for this research was provided by:
EC | European Research Council (101000948)
Agence Nationale de la Recherche (ANR-18-RHUS-005)
Agence Nationale de la Recherche (19-CE14-0030-01)
Agence Nationale de la Recherche (ANR-25-CHBS-0008)
Fondation recherche médicale (FDM202006011222)
- License Information
-
More Information
Article History
Received: 12 March 2025
Revised: 5 November 2025
Accepted: 10 November 2025
First Online: 21 November 2025
Disclosure and competing interests statement
: A patent application (“BYL719 (alpelisib) for use in the treatment of PIK3CA-related overgrowth spectrum” #WO2017140828A1) has been filed by INSERM (Institut National de la Santé et de la Recherche Médicale), Centre National De La Recherche Scientifique (CNRS), Université Paris Cité, and Assistance Publique-Hôpitaux De Paris (AP-HP) for the use of BYL719 (alpelisib) in the treatment of PIK3CA -related overgrowth spectrum (PROS/CLOVES syndrome). GC is the inventor. This patent is licensed to Novartis. GC receives or has received consulting fees from Novartis, Fresenius Medical Care, Vaderis, Alkermes, IPSEN and BridgeBio. The other authors declare no other competing interests. GC is an editorial advisory board member.
